Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing
09:05am, Tuesday, 04'th Jun 2024
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could ena
NanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicines
08:38am, Wednesday, 29'th May 2024
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and infl
NanoViricides taps Aagami to seek out licensing and partnership opportunities
09:33am, Thursday, 23'rd May 2024
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities
NanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believe
03:10pm, Tuesday, 21'st May 2024
NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy' rating and $6.50 price target by analysts at EF Hutton following the release of positive data on the anti-influenza A/H3N2 activity of its therap
NanoViricides reports strong antiviral activity of NV-387 against RSV
08:16am, Monday, 20'th May 2024
NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus (RSV) in a lethal lung infection animal model. T
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
06:30am, Monday, 20'th May 2024
NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company
NanoViricides reports strong antiviral activity of NV-387 against RSV
04:15am, Monday, 20'th May 2024
NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus (RSV) in a lethal lung infection animal model. T
NanoViricides is leveraging its unique nanoviricide platform technology to create first-in-class drugs against viruses
04:15am, Monday, 20'th May 2024
Ben Broadbent, a member of the Bank of England's rate-setting committee, said the base rate could be cut at some point this summer. Deputy governor Broadbent, who steps down next month after 13 years
NanoViricides Has Filed its Quarterly Report
06:30am, Wednesday, 15'th May 2024
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in br
NanoViricides unveils new data showing lead drug asset's strong activity against RSV
08:44am, Tuesday, 14'th May 2024
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387 in RSV/A2. The company said that animals lethally infected in their l
NanoViricides CEO discusses NV-387's broad-spectrum antiviral potential
03:21pm, Monday, 13'th May 2024
NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic NV-387. The company has recently released data f
NanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global Conference
09:01am, Friday, 10'th May 2024
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held in New York on May 15, 2024, which brings together institu
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
06:30am, Friday, 10'th May 2024
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
09:13am, Wednesday, 08'th May 2024
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the orthopoxvirus family of viruses, which includes
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
06:30am, Wednesday, 08'th May 2024
NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 8, 2024 / NanoViricides, Inc. (NYSE Ameri
